BAY 399624

Drug Profile

BAY 399624

Latest Information Update: 22 Mar 2010

Price : $50

At a glance

  • Originator Bayer
  • Class
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 09 May 2002 BAY 399624 is available for exclusive licensing in Germany [email: Arndt.Brandes.AB@bayer-ag.de]
  • 04 Sep 2000 New profile
  • 04 Sep 2000 Phase-I clinical trials for Postmenopausal osteoporosis in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top